Dowpharma extends capabilities for nucleic acid medicines production
DowpharmaSM contract manufacturing services, a business unit of The Dow Chemical Company, has added an oligonucleotide synthesiser, the OligoPilot 400, to its cGMP manufacturing offering in nucleic acid medicines.
DowpharmaSM contract manufacturing services, a business unit of The Dow Chemical Company, has added an oligonucleotide synthesiser, the OligoPilot 400, to its cGMP manufacturing offering in nucleic acid medicines.
The added capabilities of the OligoPilot 400 synthesiser build on Dowpharma's ability to meet drug makers' needs in growing application areas such as RNA interference (RNAi). It will be especially valuable for companies in early toxicology or Phase I or II clinical trials, who need quantities in the 100g range, the company said.
DowpharmaSM contract manufacturing services delivers innovative technologies, products, and services in drug discovery, development, delivery and manufacturing to pharmaceutical and biopharmaceutical companies. Its manufacturing facilities span laboratory to commercial scale, with intermediate capabilities in between.
'With the addition of this synthesiser, we will be better able to meet drug manufacturers' needs in all areas of production in nucleic acid medicines, offering greater flexibility, speed and convenience,' said Nick Hyde, business director, Dowpharma. 'This addition is another step in our continuing investment in nucleic acid medicines, an area that we believe has significant long-term potential.